Legend targets multiple IND filings (oncology, autoimmune) starting 2H 2026
Legend targets multiple IND filings (oncology, autoimmune) starting 2H 2026, expected in the second half of 2026 (no exact date yet). A company milestone for Legend Biotech (in vivo CAR-T / pipeline for oncology and autoimmune): a step in the program rather than a decision or a data readout.
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary
- Company
- Legend Biotech Corporation LEGN
- Drug
- in vivo CAR-T / pipeline
- For
- oncology and autoimmune
- Stage
- IND
- When
- H2 2026 · the company gave a window, not a day; the calendar never invents one
- Source note
- From Legend's JPM 2026 business update (Jan 12, 2026, via StockTitan mirror of company PR). The Aug 11, 2026 Q2 PR gave no dated forward milestones; LB2501 in vivo CAR-T PoC already reported at EHA 2026.
- Checked
- Checked by a person when it was added
- Source: stocktitan.net ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- LEGN headlines on this site
Legend Biotech expects to report results from its Phase 3 study of Carvykti (ciltacabtagene autoleucel) for Newly diagnosed multiple myeloma (transplant-ineligible: CARTITUDE-5; transplant-eligible: CARTITUDE-6) during 2027 (no exact date yet). Phase 3 is the last stage before a drug can be approved, so this result usually decides the program’s future.
More details
- Entry
- CARTITUDE-5 and CARTITUDE-6 event-driven Phase 3 readouts: Carvykti in frontline multiple myeloma · Clinical trial results (readout / topline data)
- Drug
- Carvykti (ciltacabtagene autoleucel)
- For
- Newly diagnosed multiple myeloma (transplant-ineligible: CARTITUDE-5; transplant-eligible: CARTITUDE-6)
- Stage
- Phase 3 · the last stage before a drug can be approved
- When
- 2027 · the company gave a window, not a day
- Source note
- Both J&J-partnered trials are fully enrolled but event-driven; management frames readouts as possible in 2026-2027 with no committed date. Dated 2027 as the midpoint of the guided window - treat as a floating catalyst.
- Checked
- Checked by a person when it was added
- Verify it
- Source: tipranks.com ↗ — where this entry was taken from
- SEC filings (8-K) ↗ — press releases are attached to 8-K filings
- ClinicalTrials.gov ↗ — trials of this drug
- LEGN headlines on this site
Plain-English summary generated from this entry’s own fields (drug, condition, stage, date). Glossary · Open this catalyst’s page